Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.
In an interview with The Center for Biosimilars®, intellectual property lawyer, Ha Kung Wong, JD, partnered with Venable LLP, discusses the impact of lawsuits on biosimilar accessibility. He mentions a recent lawsuit by Johnson & Johnson (J&J), aiming to delay biosimilar competition and other relevant legal cases.
Wong points out that antitrust suits targeting biosimilar competition are not uncommon, especially for expensive drugs. He then elaborates on 3 past lawsuits: J&J’s antitrust suit regarding Remicade (reference infliximab), the Remicade exclusionary contracting lawsuit by Pfizer, and the lawsuit regarding Humira (reference adalimumab).
While these lawsuits might have discouraged the use of exclusionary contracts, their effectiveness remains debatable due to relatively small settlements compared to the drugs' revenue. The interview concludes surrounding the uncertainty of future lawsuits' and the impact they have on biosimilar accessibility.
Transcript:
Recently, CareFirst BlueCross BlueShield filed a lawsuit against J&J alleging that the company is “scheming” to delay ustekinumab biosimilar competition. How do you expect this case to play out and what impact could it have on the overall biosimilar industry?
This is not the first antitrust suit to be filed related to a biosimilar and biosimilar competition, particularly on drugs that are costly so it really isn't surprising to see another antitrust suit.
As a side note, talking about antitrust always reminds me of the 2001 movie Antitrust starring Ryan Phillippe and Rachael Leigh Cook, but I digress.
Previous antitrust suits, you know that I think we want to think about in conjunction with this one would be the Remicade exclusionary contracting class action lawsuit. That actually was settled by consumers, third party payers for $25 million.
There was the Remicade exclusionary contracting lawsuit by Inflectra biosimilar manufacturer, Pfizer. There was an undisclosed settlement agreement there.
Then the Humira lawsuit, which found that filing numerous patent applications was a form of petitioning the government, qualified for Noerr-Pennington immunity and that protects the filing under the First Amendment petition and free speech clause.
Even if the petition is anticompetitive, it's immune from antitrust action. I bring those up because so far, the biosimilar antitrust suits may have had some positive impact on decreasing the usage of exclusionary contracts to prevent biosimilar formulary coverage.
However, it's yet to be seen maybe debatable how steep of a deterrent something like a $25 million settlement is on a drug similar to Remicade, which is making over $6 billion a year.
It’s unclear whether another antitrust lawsuit will have a significant impact on biosimilars going forward or not. But certainly something that we should keep an eye on and certainly something we should be vigilant about.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.